Unlocking The Potential of IER5: A Protein with Unique Structure and Diverse Functions

Target Name: IER5

NCBI ID: G51278

IER5

Other Name(s): SBBI48 | Immediate early response 5 | Immediate early response gene 5 protein | IER5_HUMAN | immediate early response 5

Unlocking The Potential of IER5: A Protein with Unique Structure and Diverse Functions

IER5 (Integrin-Like Protein 5) is a protein that is expressed in various tissues throughout the body, including the nervous system, immune system, and connective tissue. It is a member of the integrin family, which is a large family of transmembrane proteins that play a critical role in cell-cell and cell-extracellular matrix interactions.

One of the unique features of IER5 is its structure. It is a type of integrin that consists of an alpha chain and a beta chain that are fused together. The alpha chain has four constant residues, while the beta chain has one variable residue. This fusion of the two chains creates a unique structure that allows IER5 to interact with various cell surface molecules.

IER5 has been shown to play a critical role in several physiological processes in the body. For example, it is involved in the development and maintenance of the blood-brain barrier, which is responsible for protecting the brain from harmful substances. IER5 has also been shown to be involved in the regulation of pain, and has been linked to the development of chronic pain conditions.

In addition to its role in the immune system, IER5 has also been shown to play a critical role in the regulation of inflammation. It is involved in the production of pro-inflammatory cytokines, which are important for the initial response to an infection.

Despite its importance, IER5 has not yet been identified as a drug target or biomarker. This is because the study of integrins and their associated proteins has only recently become a focus of interest, and because there are still many unanswered questions about the function of IER5 and its potential role in disease.

However, with the increasing understanding of the complex role of integrins in various physiological processes, it is possible that IER5 will soon be identified as a drug target or biomarker. This could have a significant impact on the treatment of diseases that are currently difficult to treat, such as chronic pain and immune-related disorders.

In conclusion, IER5 is a protein that is expressed in various tissues throughout the body, and has been shown to play a critical role in several physiological processes in the body. While it has not yet been identified as a drug target or biomarker, its unique structure and its involvement in important physiological processes make it an attractive target for future research.

Protein Name: Immediate Early Response 5

Functions: Plays a role as a transcription factor (PubMed:22132193, PubMed:25355627). Mediates positive transcriptional regulation of several chaperone genes during the heat shock response in a HSF1-dependent manner (PubMed:25355627, PubMed:25816751). Mediates negative transcriptional regulation of CDC25B expression (PubMed:22132193). Plays a role in the dephosphorylation of the heat shock factor HSF1 and ribosomal protein S6 kinase (S6K) by the protein phosphatase PP2A (PubMed:25816751, PubMed:26496226). Involved in the regulation of cell proliferation and resistance to thermal stress (PubMed:22132193, PubMed:25355627, PubMed:26496226). Involved in the cell cycle checkpoint and survival in response to ionizing radiation (PubMed:19238419, PubMed:22132193). Associates with chromatin to the CDC25B promoter (PubMed:22132193)

The "IER5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IER5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets